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 Prion diseases, such as sporadic Creutzfield-Jakob disease (sCJD) in humans, are a 
family of neurodegenerative conditions that are derived from the misfolding of proteins (Lukic et 
al., 2014). Specifically, a GPI-anchored protein called the prion protein (PrPC) which is thought 
to be involved in cell adhesion and inhibition of apoptosis, can be converted into a harmful 
variant known as PrPSc. In this abnormal isoform, PrPSc essentially aids in the conversion of 
other normal prion proteins, leading to an aggregation of misfolded proteins. Although the 
methods of conversion to PrPSc are still largely unknown, it has been determined that 
aggregation can lead to deficits in both neural and motor function by causing apoptosis of 
neurons (Dalai, Matsuo, Takeyama, Kawano & Saeki, 2016). Researchers have begun to study 
the genetic factors related to the likelihood of contracting a prion disease, and the prion protein 
gene (PRNP) is at the forefront of the discussion. Allelic variation in PRNP codon 129 in 
humans, and PrPC codon 222 in sheep, have been associated with differences in susceptibility of 
developing prion diseases (Atkins, Townsend, Medlock & Galvani, 2013; Aguilar-Calvo et al., 
2013). Scientists are also looking into how the activity of promoters, enhancers and repressors 
effects PRNP gene expression, and consequently prion formation (Dalai, Matsuo, Takeyama, 
Kawano & Saeki, 2016). Additionally, the extracellular matrix has been a point of interest in 
prion disease research because several genes associated with resistance to prion formation are 
related to transport of PrPC into the extracellular matrix (Imerdis and Harris, 2014). While prion 
diseases can be acquired through mutation, they can also develop from the consumption of 
infected flesh, such as in Kuru and Bovine Spongiform Encephalopathy (BSE), more commonly 
known as ‘Mad Cow Disease’. Regardless of the method of contraction, prion diseases can be 
extremely detrimental to one’s quality of life and may eventually lead to death (Atkins, 
Townsend, Medlock & Galvani, 2013). Research into the genetic causes of susceptibility to prion 
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disease contraction has pointed to variation in PRNP and PrPC, as well as genes associated with 
the extracellular matrix, as the keys to developing future treatments for prion disease.  
Specific codons in the PRNP gene have been examined in relation to susceptibility and 
resistance to prion diseases. Prior research has signified codon 129 in PRNP as a potential factor 
in the progression of prion disease development (Atkins, Townsend, Medlock & Galvani, 2013). 
There are two possible alleles at codon 129, amino acids methionine or valine. Therefore, it is 
possible to be homozygous for either one of the amino acids, or heterozygous and have both of 
the amino acids. To study the relevance of PRNP codon 129 in one’s susceptibility to prion 
disease, residents of the Fore population of Papua New Guinea who were exposed to the 1950’s 
Kuru epidemic were evaluated. Kuru is a prion disease that spread quickly through the small 
tribal population due to ritualistic consumption of the flesh of members who had died. Although 
cannibalism was banned in the population in 1959, deaths due to Kuru are still occurring due to 
the lengthy incubation period of the disease. Therefore, studying the genomes of the epidemic’s 
survivors has the potential to provide information about genetic factors that contributed to their 
decreased susceptibility to Kuru contraction. Using a population genetics approach, researchers 
studied data regarding the frequency of genotypes using various models and mortality data to 
determine whether there was an advantage to allelic homozygosity or heterozygosity at codon 
129. The results of the study concluded that of those exposed to the Kuru epidemic in Papua 
New Guinea, heterozygotes for codon 129 contracted the disease less frequently than 
homozygotes at the locus. In addition, heterozygotes for codon 129 had longer incubation rates if 
they did develop the disease, which in turn increased life longevity (Atkins, Townsend, Medlock 
& Galvani, 2013). This means that the presence of both methionine and valine at codon 129 in 
the PRNP gene is advantageous to having just one of the two amino acids for both alleles, and is 
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related to a decreased genetic susceptibility to the prion disease Kuru. These findings exhibit that 
variation at the codon level can be attributed to the susceptibility of developing Kuru, and should 
be expanded to other prion diseases to generate a potentially wider impact in future treatments. 
While it is unlikely that prion susceptibility is limited to variance at just one codon in the PRNP 
gene, this study could be a starting point for determining how resistance to prion diseases can be 
attained.  
Another approach to examining what factors contribute to one’s susceptibility to prion 
disease development lies in the expression of the PRNP gene, which regulates the impact that 
allelic variation can have on the function of the gene. Gene expression depends on multiple 
factors such as the activity at the gene’s promoter or enhancer, which can be transcriptionally 
repressed due to methylation. A gene’s promoter sequence is a stretch of DNA at which 
transcription begins, and is therefore an essential component of gene expression. Enhancers are 
located upstream of the promoter sequence, and can be bound by transcription factors to increase 
transcription rates, and thus intensify expression of the gene. Both enhancers and promoters can 
be methylated, which entails adding methyl groups to the sequences and subsequently repressing 
transcription of the gene by inhibiting binding of the DNA (Core, Martins, Danko, Waters, 
Siepel, & Lis, 2014). Areas called CpG islands are common in promoter regions, and consist of a 
higher number of cysteine and guanine bases than normally found in DNA. CpG islands have an 
increased likelihood of being methylated so that they are not expressed. A recent study looked 
into the methylation status of CGIs, long stretches of CpG islands, in the promoter of PRNP to 
investigate how the gene’s regulation effected its’ expression (Dalai, Matsuo, Takeyama, 
Kawano & Saeki, 2016). Using mice, researchers determined that the PRNP promoter sequence, 
located between CpGs 20-40, was completely unmethylated, while the enhancer region, which 
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was found to be between CpGs 1-7, had variable methylation of CpG islands. Specifically, 
CpG2, which typically binds to a repressor element, was found to be unmethylated when PRNP 
was not expressed. Repressors are proteins that bind to promoter sequences and restrict 
transcription by obstructing the binding of RNA polymerase, which inhibits transcription of the 
gene. Therefore, this means that when CpG2 is methylated and the repressor is unable to bind to 
the promoter sequence, the prion protein gene is expressed in the cell because transcription by 
RNA polymerase can occur. This finding has also led researchers to believe that under certain 
conditions, such as at the fetal stage of mouse development, the repressor typical of this binding 
region, Hes1, may be blocked from binding to the DNA due to the presence of an enhancer. 
Finally, the study considered the role of the gene’s insulator, CTCF, which obstructs the 
association between the promoter and the enhancer or repressor, as well as effects gene 
expression through chromatin remodeling. It was determined that the insulator element was 
located near CpG2, which supports the notion that CpG2 methylation is an important component 
in PRNP gene expression (Dalai, Matsuo, Takeyama, Kawano & Saeki, 2016). This information 
has contributed to the conclusion that variable methylation of the PRNP promoter and enhancer 
could occur during different developmental periods and in different cell types. This could lead to 
expression of the prion protein gene in certain parts of the body during different stages of 
growth, and could affect one’s susceptibility to developing prion disease. This new 
understanding of the expression of PRNP is a powerful addition to our comprehension of the 
genetic components that contribute to prion disease contraction and could aid in its eventual 
treatment. 
While it is important to study human data regarding prion disease development, looking 
into related diseases in animals could be a useful tool in determining the genetic causes and 
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developing treatments in humans. Similar to the role of codon 129 in human prion disease, PrPC 
codon 222 in sheep is thought to be a determinant of sheep’s susceptibility to prion diseases such 
as scrapie (Aguilar-Calvo et al., 2013). One study looked into how amino acid variations in PrPC 
affected the susceptibility of transgenic mice to various prion diseases. Researchers studied mice 
that were homozygous for the wild type amino acid, 𝑄𝑄222 or glutamine, homozygous for the 
variant amino acid, 𝐾𝐾222 or lysine, and heterozygous for both amino acids. Mice of each 
genotype were exposed to scrapie, cattle BSE and goat BSE, all forms of prion disease, and their 
reactions were recorded. The study concluded that the mice that were homozygous for lysine, the 
variant amino acid, were completely resistant to infection from scrapie and cattle BSE, and 
heterozygotes were less susceptible to contraction than mice expressing only glutamine, the wild 
type amino acid. Although the mode of resistance is still unclear, it appears as if the presence of 
the variant amino acid at codon 222 inhibited the proliferation of prion protein (Aguilar-Calvo et 
al., 2013). Therefore, by simply having lysine instead of glutamine at both alleles of codon 222, 
the development of prion disease was entirely averted in the transgenic mice, similarly to how 
heterozygosity at codon 129 in the human PRNP gene greatly decreased contraction of Kuru in 
exposed individuals in Papua New Guinea (Atkins, Townsend, Medlock & Galvani, 2013). 
Although these findings are in different animals and in alternate levels of genetic material, they 
are both applicable to the determination of the factors that affect the susceptibility of developing 
prion disease. Specifically, the results of this study can be directly incorporated into selective 
breeding programs for prion resistance in goats, but can also be expanded to encompass other 
populations. If this research can be altered and applied to human prion disease as well, there is 
huge potential for the development of genetic resistance to prion disease in both humans and 
animals.  
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Although all of the studies discussed thus far have focused on the specific PRNP and 
PrPC codons that play a role in the development and resistance to prion diseases, it is also 
important to consider alternate genes that could affect one’s susceptibility to contraction. 
Imberdis and Harris (2014) reviewed a study completed by Marbiah et al. (2014) in which the 
cellular roles of genes associated with prion disease were analyzed. Remarkably, the study 
showed that many of the genes that were related to prion resistance were also associated with the 
extracellular matrix. The extracellular matrix surrounds cells and consists of an assortment of 
extracellular components that assist the cell both structurally and developmentally by regulating 
tissue specific homeostasis (Mouw, Ou, & Weaver, 2014). One of the genes of interest from the 
study, Fn1, was found to have a negative relationship with the amount of PrPSc present in the 
extracellular matrix when it was expressed. Researchers concluded that inhibition of Fn1 and a 
related gene, Papss2, led to an increase in the amount of PrPC discovered in the extracellular 
matrix. An increased presence of PrPC in the extracellular matrix means that there is more 
protein available to be converted to the isoform, PrPSc, which therefore increases the cells’ 
susceptibility to developing prion disease. Therefore, increasing the expression of genes such as 
Fn1 and Papss2 through the utilization of transcriptional equipment, such as the genes’ 
enhancers and promoters, could impede the progression of prion disease by limiting the 
availability of normal prion protein that can be converted to the harmful variant. Consequently, 
this study has shown that the extracellular matrix and the genes that are associated with it have 
the potential to be hubs for drug treatments of prion diseases due to their relationship with the 
conversion of the prion protein to its isoform (Imerdis and Harris, 2014). Therefore, the future of 
prion resistance studies should not be limited to only research on the PRNP gene or PrPC protein, 
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but also explore the roles of genes related to the conversion of PrPC to PrPSc in the extracellular 
matrix. 
Although much research must still be done to determine all of the genetic factors that 
effect one’s susceptibility to prion disease formation, the future of genetically based treatment of 
prion diseases seems to lie in the allelic variation and regulation at multiple gene loci. Research 
on human prion disease data has pointed to variation in PRNP codon 129 as a factor in prion 
disease formation, and animal research has denoted PrPC codon 222 as another topic of interest 
that should be investigated further (Atkins, Townsend, Medlock & Galvani, 2013; Aguilar-Calvo 
et al., 2013). In addition to specific variable components of the PRNP coding gene, there seems 
to be promise in the methylation patterns of non-coding regulatory regions of PRNP as a 
probable contributor to prion disease manifestation (Dalai, Matsuo, Takeyama, Kawano & Saeki, 
2016). Conversely, studies have also investigated the expression of other genes, such as Fn1 and 
Papss2, which are associated with the extracellular matrix and may be related to the propagation 
of the variant version of the prion protein. This relationship points to the extracellular matrix, 
and the proteins that effect its behavior, as potential targets for future drug treatment research 
(Imberdis & Harris, 2014). In recent years, scientists have also begun to question whether or not 
the site of conversion of PrPC to PrPSc is relevant to prion disease progression, which could be 
another promising component of the picture to explore (Cracco et al., 2017). While our 
understanding of many of the genetic components that effect susceptibility to prion disease is 
advancing, more research must be conducted before development of a treatment for this 
debilitating family of diseases can begin. Additionally, due to the likeness of more common 
neurodegenerative ailments such as Parkinson’s and Alzheimer’s diseases to prion disease, it is 
    
 
9 
possible that any findings regarding the genetic susceptibility of developing one of the diseases 
may be applicable to treatment of the others, and therefore benefit a wider range of individuals. 
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